Key result
Carrying the tPA -7,351T allele is linked to ~2.7-fold higher odds of first MI.
Case-Control (n=181)
Answers are grounded in this paper and cite their sources.
We recently identified a polymorphic Sp1 binding site in an enhancer at the tissue-type plasminogen activator (tPA) locus (tPA -7,351C/T), which was associated with vascular tPA release. Subjects homozygous for the -7,351C allele had twice the tPA release rate compared to subjects carrying the -7,351T allele. In this study we tested the hypothesis that the tPA -7,351C/T polymorphism is associated with myocardial infarction (MI). In a population-based prospective nested case-control study within northern Sweden, genotypes were determined among 61 MI cases and 120 controls. In a multivariate model, the tPA -7,351C/T polymorphism (OR 2.68 for T allele carriers; 95% CI 1.31-5.50), tPA antigen (OR 1.16; 95% CI 1.07-1.25) and apo A-I (OR, 0.997; 95% CI 0.995-0.999) were independently associated with a first MI. These findings suggest that genetic markers of local tPA release and circulating steady-state tPA levels carry independent prognostic information.
No takes yet. Share an insight, caveat, or question.
Jansson et al. (2002) conducted a case-control in First myocardial infarction (n=181). tPA -7,351C/T enhancer polymorphism (T allele carrier status) vs. Homozygous -7,351C allele carriers was evaluated on First myocardial infarction (OR 2.68, 95% CI 1.31-5.50). Carrying the tPA -7,351T allele was independently associated with an increased risk of a first myocardial infarction (OR 2.68; 95% CI 1.31-5.50).
Synapse has enriched 10 related papers. Consider them for comparative context: